MPG.eBooks - Search Results

Cover Image

1

Sarilumab (Kevzara)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

2

Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have r...

Published 2014

Canadian Agency for Drugs and Technologies in Health

Cover Image

3

Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

4

Patient group input submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or photothe...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

5

Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

6

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Cover Image

7

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

8

Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

9

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

10

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

11

Patient group input submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or photothe...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

12

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

13

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Cover Image

14

Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have r...

Published 2014

Canadian Agency for Drugs and Technologies in Health

Cover Image

15

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

16

Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

17

Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

18

Sarilumab (Kevzara)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

19

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Cover Image

20

Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Published 2017

Canadian Agency for Drugs and Technologies in Health

1
2